Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Rosuvastatin escape in a Chinese elderly with hyperlipidemia.

Chen XJ, Cheng L, Chu JJ, Chen J, Tang XF, Zhang XF.

Chin Med J (Engl). 2013;126(18):3578-9. No abstract available.

2.

Effect of rosuvastatin treatment on plasma visfatin levels in patients with primary hyperlipidemia.

Kostapanos MS, Derdemezis CS, Filippatos TD, Milionis HJ, Kiortsis DN, Tselepis AD, Elisaf MS.

Eur J Pharmacol. 2008 Jan 14;578(2-3):249-52.

PMID:
17931620
3.

Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients.

Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G.

Atherosclerosis. 2006 Jan;184(1):233-4. No abstract available.

PMID:
16168995
4.

Rosuvastatin receives FDA approval.

[No authors listed]

Cardiovasc J S Afr. 2003 Sep-Oct;14(5):286. No abstract available.

5.

Statins: how far have we come? A review of rosuvastatin.

Olsson A.

Int J Clin Pract Suppl. 2003 Oct;(137):15-25. Review. No abstract available.

PMID:
14649698
6.

Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.

Katsiki N, Athyros VG, Karagiannis A, Mikhailidis DP.

J Clin Lipidol. 2012 Jan-Feb;6(1):93. doi: 10.1016/j.jacl.2011.09.002. No abstract available.

PMID:
22264581
7.

Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.

Capuzzi DM, Morgan JM, Carey CM, Intenzo C, Tulenko T, Kearney D, Walker K, Cressman MD.

Prev Cardiol. 2004 Fall;7(4):176-81.

8.

Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular risk.

Nicholls SJ, Uno K, Kataoka Y.

Expert Rev Cardiovasc Ther. 2011 Nov;9(11):1383-90. doi: 10.1586/erc.11.145. Review.

PMID:
22059787
9.

Starting with rosuvastatin in primary hyperlipidemia--Is there more than lipid lowering?

Milionis HJ, Gazi IF, Filippatos TD, Tzovaras V, Chasiotis G, Goudevenos J, Seferiadis K, Elisaf MS.

Angiology. 2005 Sep-Oct;56(5):585-92.

PMID:
16193198
10.

[JUPITER study (2). For now no reason to give statins to more people].

Koopmans RP.

Ned Tijdschr Geneeskd. 2009 Feb 7;153(6):218-9. Dutch. No abstract available.

PMID:
19271439
11.

Treatment and prevention of dyslipidemia with rosuvastatin (Crestor).

Leonard KA.

Nurse Pract. 2004 May;29(5):11-5. Review. No abstract available.

PMID:
15167530
12.

[JUPITER study, more reason to give statins as preventive measure - commentary].

Narkiewicz K.

Kardiol Pol. 2009 Mar;67(3):346-7. Polish. No abstract available.

13.

Is hsCRP Back on Board? Implications from the JUPITER Trial.

Koenig W.

Clin Chem. 2009 Feb;55(2):216-8. doi: 10.1373/clinchem.2008.115915. No abstract available.

14.
15.

Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease.

Verma A, Ranganna KM, Reddy RS, Verma M, Gordon NF.

Am J Cardiol. 2005 Nov 1;96(9):1290-2.

PMID:
16253600
16.

Rosuvastatin in the management of hyperlipidemia.

Cheng JW.

Clin Ther. 2004 Sep;26(9):1368-87. Review.

PMID:
15531000
17.

Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance.

Kennedy SP, Barnas GP, Schmidt MJ, Glisczinski MS, Paniagua AC.

J Clin Lipidol. 2011 Jul-Aug;5(4):308-15. doi: 10.1016/j.jacl.2011.03.454.

PMID:
21784377
18.

Two more drugs for dyslipidemia.

Roberts WC.

Am J Cardiol. 2004 Mar 15;93(6):809-11. No abstract available.

PMID:
15019903
19.

Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.

Durrington PN, Tuomilehto J, Hamann A, Kallend D, Smith K.

Diabetes Res Clin Pract. 2004 May;64(2):137-51.

PMID:
15063607
20.

Complications and side effects. Crestor tested in PHAs.

[No authors listed]

TreatmentUpdate. 2005 Jun-Jul;17(4):6-7. No abstract available.

PMID:
17230630
Items per page

Supplemental Content

Support Center